The Eleventh Annual Blood-Brain Barrier Consortium Meeting is scheduled for March 17-19, 2005, in Portland OR. The overall hypothesis of the meeting is that increased delivery of therapeutics in CNS malignancy and neurological diseases can improve survival and quality of life without increased systemic or neurological toxicity. The goals of the meeting are to review basic science, preclinical, and clinical research on the BBB, brain tumors, and neurological diseases. Every meeting spotlights new areas in which research advances may impact brain delivery, imaging, or therapy. The scientific session topics for the 2005 meeting will be 1) Cell and Molecular imaging, 2) Nanotechnology and nanomedicine, and 3) Chemoprotection. Half of each meeting is devoted to the development of new clinical protocols. In 2005, the clinical sessions will concentrate on 1) clinical protocol development to increase delivery to primary and metastatic brain tumors, 2) Chemoprotection, and 3) MR imaging of malignant brain tumors and CNS lesions. Five publications have been developed from previous meetings regarding dose intensity versus neurotoxicity in neuro-oncology clinical trials, targeted delivery in primary and metastatic brain tumors, and strategies for prevention of toxicity. Attendance at the annual BBB meeting is encouraged for principal investigators, clinical staff, and researchers from the participating institutions of the BBB Consortium. Distinguished scientists are invited to attend, as well as clinicians and researchers from OHSU, NIH, and other universities with research programs in the BBB and neuro-oncology, with a particular emphasis on translational research. We encourage and recruit the participation of minority, women and disabled clinicians and scientists. The 2005 BBB meeting will continue to provide a forum for the BBB Consortium to meet fellow researchers, translate preclinical research to the clinic, and develop multi-center protocols to determine optimal treatment strategies for chemo-sensitive brain tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Conference (R13)
Project #
3R13CA086959-10S1
Application #
8040070
Study Section
Special Emphasis Panel (ZCA1-GRB-T (J1))
Program Officer
Wu, Roy S
Project Start
2000-04-05
Project End
2011-03-31
Budget Start
2009-04-01
Budget End
2011-03-31
Support Year
10
Fiscal Year
2010
Total Cost
$5,000
Indirect Cost
Name
Oregon Health and Science University
Department
Neurology
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Brock, Penelope R; Maibach, Rudolf; Childs, Margaret et al. (2018) Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med 378:2376-2385
Doolittle, Nancy D; Muldoon, Leslie L; Culp, Aliana Y et al. (2014) Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances. Adv Pharmacol 71:203-43
Neuwelt, Edward A; Bauer, Björn; Fahlke, Christoph et al. (2011) Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci 12:169-82
Angelov, Lilyana; Doolittle, Nancy D; Kraemer, Dale F et al. (2009) Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol 27:3503-9
Neuwelt, Edward; Abbott, N Joan; Abrey, Lauren et al. (2008) Strategies to advance translational research into brain barriers. Lancet Neurol 7:84-96
Muldoon, Leslie L; Soussain, Carole; Jahnke, Kristoph et al. (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25:2295-305
Doolittle, Nancy D; Peereboom, David M; Christoforidis, Gregory A et al. (2007) Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting. J Neurooncol 81:81-91
Muldoon, L L; Tratnyek, P G; Jacobs, P M et al. (2006) Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting. AJNR Am J Neuroradiol 27:715-21
Doolittle, Nancy D; Abrey, Lauren E; Bleyer, W Archie et al. (2005) New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res 11:421-8
Smith, Justine R; Rosenbaum, James T; Wilson, David J et al. (2002) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109:1709-16

Showing the most recent 10 out of 13 publications